NEWLINK GENETICS CORP NLNK Cash Flow

Newlink genetics corp (NLNK)

CashFlow / TTM

Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash Flows From Operating Activities
Net loss
-42,989	-45,287	-38,142	-45,321	-53,595	-56,712	-69,935	-69,348	-71,951	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	-	0	0	0	-	0	0	0	-	-22,812	-20,947	-19,032	-18,088	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation
6,722	9,476	11,840	14,244	17,120	17,190	16,937	17,353	18,508	18,526	18,031	17,966	16,707	16,665	16,063	17,465	15,940	14,106	14,130	9,699	8,613	8,132	5,942	5,504	4,365	3,795	3,317	3,425	3,195	3,669	3,471	2,913	2,545	0	0	0
Depreciation and amortization
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,145	1,097	1,070	983	935	891	850	841	825	788	0	0	0	-	-	-	-
Depreciation and amortization
1,645	676	907	1,019	1,145	1,244	1,337	1,381	1,407	1,612	1,587	1,849	2,084	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Forgiveness of debt
-	-	-	-	-	-	-	-	-	-	-	-	397	397	397	397	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Impairment of fixed assets
-	-	-	-	-	-	-	-	-	-	-	-	3,958	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on sale of fixed assets
-20	-158	-141	-122	-102	-8	21	-97	-126	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-58	-38	-20	20	20	0	0	0	0
Amortization of right-of-use assets
-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
In-process research and development expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	0	0	0	0
Forgiveness of debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	0	0	0	0
Forgiveness of notes receivable from related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	0	0	0	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
-2,491	-1,609	-1,228	-1,168	-226	2,683	791	-2,904	305	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and other current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-8,393	-	1,416	10,899	10,547	7,561	-52	-89	22	-134	260	-29	131	498	-672	276	249	550	0	0	0
State research and development credit receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-147	-316	-78	62	-210	-213	103	363	470	340	370	-242	-97	28	0	0	0
Interest due on notes receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Other receivables
296	40	-359	-10,047	-10,223	-10,476	-10,947	201	-14,350	-4,324	8,079	2,832	19,139	18	-9,815	-4,232	1,672	12,257	12,834	10,795	2,388	1,497	-652	-206	1,132	1,197	1,632	985	0	319	-534	-243	416	0	0	0
Accounts payable and accrued expenses
1,979	2,296	-7,937	-11,970	-13,029	-15,718	-9,975	-7,625	-15,469	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	117	-	2,629	3,875	9,656	7,898	4,330	755	820	843	55	290	27	-909	-28	-218	-268	637	0	0	0
Income taxes receivable, net
421	7,393	7	-2	17	-7,424	5,787	5,808	5,479	5,083	-2,028	-4,491	-6,834	-5,121	-8,581	5,553	9,622	7,427	4,318	-7,353	-8,892	-7,502	5	5	130	0	0	0	-	-	-	-	-	-	-	-
Unearned revenue
0	0	0	0	-56	-112	-167	-223	-335	259	113	-24	-68	-816	-852	-3,415	-12,752	1,509	1,746	4,502	14,051	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent
0	14	41	67	92	102	98	94	91	896	897	899	908	90	87	83	73	83	82	83	83	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-30,207	-23,493	-31,670	-30,776	-37,939	-53,833	-45,979	-49,948	-48,281	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Accrued expenses and deferred rent
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	1,011	956	659	276	0	0	0
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-41,273	-	114,942	113,460	112,814	109,068	-29,671	-27,444	-25,262	-25,818	-24,417	-21,499	-21,454	-20,471	0	0	0	-	-	-	-
Cash Flows From Investing Activities
Purchase of certificates of deposit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,992	1,992	4,482	2,490	2,490	2,490	0	0	0
Maturity of certificates of deposit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-9,851	-5,233	0	-249	-747	-1,494	-2,739	-2,490	-3,735	-2,988	-1,743	-1,993	-2,000	-2,269	0	0	0
Maturity of certificates of deposit
-	-	-	-	-	-	-	-	-	-	-	-	2,180	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Notes receivable from related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	0	0	0	0
Purchase of equipment
-	-	-	-	-	-	-	-	43	220	319	2,000	2,246	2,614	3,806	3,543	3,995	3,806	3,576	2,340	1,700	1,450	1,409	1,417	1,386	1,466	483	676	1,323	1,324	1,341	942	281	0	0	0
Proceeds on sale of equipment
77	21	25	46	124	187	190	315	254	185	172	22	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	0	50	50	50	50	0	0	0	0
Cash paid for OncoRx
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	0	0	0	0
Net cash provided by investing activities
77	21	25	39	117	180	197	307	211	-35	-147	-981	-66	602	396	3,235	6,218	9,614	-7,529	-9,866	-13,844	-18,086	-1,409	-919	-141	1,273	15	1,067	-277	-4,013	-1,788	-1,382	-502	0	0	0
Cash Flows From Financing Activities
Cash received from noncontrolling interest investment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	0	0	0	0
Issuance of common stock, net of offering costs
0	-239	-206	-106	0	54,100	74,199	74,459	74,416	18,899	-122	20	0	-2,010	-1,994	-1,365	13,534	15,420	14,428	13,703	27,572	46,316	46,188	46,133	66,357	48,659	48,865	49,058	158	38,478	38,283	37,709	37,574	0	0	0
Repurchase of common stock
36	42	45	46	275	296	307	313	289	329	314	319	82	233	233	292	561	341	381	309	222	222	182	182	0	0	0	0	4	-9	-9	-9	-13	0	0	0
Principal payments on notes payable
-	0	0	112	-	0	0	261	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayments of notes receivable for common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Proceeds from preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	5,000	5,000	0	0	0
Proceeds from notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	456	456	456	0	0	0	0	0	0
Principal payments on notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	227	-	216	206	188	187	153	152	150	149	147	134	121	107	94	91	92	92	0	0	0
Payments under capital lease obligations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	33	37	43	66	88	118	124	122	124	116	125	126	0	0	0
Net cash (used in) provided by financing activities
-59	-62	-49	30	-148	55,012	75,071	75,292	75,288	20,545	1,543	1,684	1,883	7,818	7,845	8,431	23,085	21,515	20,585	19,932	33,889	46,863	46,675	46,616	67,000	49,551	50,196	50,396	1,508	38,712	38,072	42,488	42,369	0	0	0
Net decrease in cash and cash equivalents
-	-	-	-30,707	-	-	-	25,651	-	-27,574	-52,750	-58,746	-64,130	-48,865	-42,850	-29,607	5,216	146,071	126,516	122,880	129,113	-894	17,822	20,435	41,041	26,407	28,712	30,009	-19,240	19,270	20,777	26,853	28,918	0	0	0
Supplemental disclosure of cash flows information:
Cash paid for interest
-	-	-	6	-	-	-	14	-	15	18	19	22	86	107	106	105	45	23	28	26	27	29	30	34	36	36	36	38	38	47	41	42	0	0	0
Cash paid for taxes, net
-	0	0	0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,581	5,580	4,814	31,108	26,698	26,698	26,443	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Purchased leasehold improvements and equipment in accounts payable
-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Equipment acquired by capital lease
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Forgiveness of debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accretion on redeemable preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	1	3	8	8	0	0	0
Purchased leasehold improvements and equipment in accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	452	409	-145	18	1	0	193	102	-111	53	462	503	654	481	0	0	0
Common stock issued to shareholders of OncoRx as part of acquisition
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	0	0	0	0
Issuance of common stock dividend to Series AA preferred shareholders
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	1	1	1	1	0	0	0
Assets acquired under capital lease
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	0	0	0	5	80	80	0	0	0
Reduction of IPO offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	158	158	0	0	0	-	-	-	-